Journal of Cardiac Failure
Volume 15, Issue 3 , Pages 191-198 , April 2009

Endothelial Nitric Oxide Synthase (NOS3) Polymorphisms in African Americans With Heart Failure: Results From the A-HeFT Trial

  • Dennis M. McNamara, MD

      Affiliations

    • University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
    • Corresponding Author InformationReprint requests: Dennis M McNamara, MD, Heart Failure/Transplantation Program, University of Pittsburgh Medical Center, 566 Scaife Hall, 200 Lothrop Street, Pittsburgh, PA 15241. Tel: 412-648-6598; Fax: 412-648-6101.
    • ,
  • S. William Tam, PhD

      Affiliations

    • NitroMed Inc, Lexington, Massachusetts
    • ,
  • Michael L. Sabolinski, MD

      Affiliations

    • NitroMed Inc, Lexington, Massachusetts
    • ,
  • Page Tobelmann, BS

      Affiliations

    • University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
    • ,
  • Karen Janosko, MSN

      Affiliations

    • University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
    • ,
  • Lakshmi Venkitachalam, PhD

      Affiliations

    • University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
    • ,
  • Elizabeth Ofili, MD

      Affiliations

    • Morehouse School of Medicine, Atlanta, Georgia
    • ,
  • Clyde Yancy, MD

      Affiliations

    • Baylor University Medical Center, Dallas, Texas
    • ,
  • Arthur M. Feldman, MD, PhD

      Affiliations

    • Thomas Jefferson Medical College, Philadelphia, Pennsylvania
    • ,
  • Jalal K Ghali, MD

      Affiliations

    • Wayne State University School of Medicine, Detroit, Michigan
    • ,
  • Anne L. Taylor, MD

      Affiliations

    • Columbia University Medical Center, New York, New York
    • ,
  • Jay N. Cohn, MD

      Affiliations

    • University of Minnesota, Minneapolis, Minnesota
    • ,
  • Manuel Worcel, MD

      Affiliations

    • NitroMed Inc, Lexington, Massachusetts

Received 14 December 2007 ,Revised 14 October 2008 ,Accepted 23 October 2008.

References 

  1. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1986;314:1547–1552
  2. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail. 1999;5:178–187
  3. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303–310
  4. Taylor AL. The African-American Heart Failure Trial (A-HeFT): rationale and methodology. J Card Fail. 2003;9(5 Suppl Nitric Oxide):S216–S219
  5. Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R, Ferdinand K, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049–2057
  6. Angus DC, Linde-Zwirble WT, Tam SW, Ghali JK, Sabolinski ML, Villagra VG, et al. Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for blacks with heart failure. Circulation. 2005;112:3745–3753
  7. Kojda G, Kottenberg K. Regulation of basal myocardial function by NO. Cardiovasc Res. 1999;41:514–523
  8. Drexler H. Nitric oxide synthases in the failing human heart: a double-edged sword?. Circulation. 1999;99:2972–2975
  9. Heymes C, Vanderheyden M, Bronzwaer JGF, Shah AM, Paulus WJ. Endomyocardial nitric oxide synthase and left ventricular preload reserve in dilated cardiomyopathy. Circulation. 1999;99:3009–3016
  10. Kelly RA, Balligand JL, Smith TW. Nitric oxide and cardiac function. Circ Res. 1996;79:3
  11. Wang XL, Mahaney MC, Sim AS, Wang J, Wang J, Blangero J, et al. Genetic contribution of the endothelial constitutive nitric oxide synthase gene to plasma nitric oxide levels. Arterioscler Thromb Vasc Biol. 1997;17:3147–3153
  12. Marsden PA, Heng HH, Scherer SW, Stewart RJ, Hall AV, Shi XM, et al. Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J Biol Chem. 1993;268:17478–17488
  13. Wattanapitayakul SK, Mihm MJ, Young AP, Bauer JA. Therapeutic implications of human endothelial nitric oxide synthase gene polymorphism. Trends Pharmacol Sci. 2001;22:361–367
  14. Metzger IF, Souza-Costa DC, Marroni AS, Nagassaki S, Desta Z, Flockhart DA, et al. Endothelial nitric oxide synthase gene haplotypes associated with circulating concentrations of nitric oxide products in healthy men. Pharmacogenet Genom. 2005;15:565–570
  15. Jáchymová M, Horký K, Bultas J, Kozich V, Jindra A, Peleska J, et al. Association of the Glu298Asp polymorphism in the endothelial nitric oxide synthase gene with essential hypertension resistant to conventional therapy. Biochem Biophys Res Commun. 2001;284:426–430
  16. Czarnecka D, Kawecka-Jaszcz K, Stolarz K, Olszanecka A, Dembińska-Kieć A, Kieć-Wilk B. Ambulatory blood pressure, left ventricular mass and vascular phenotypes in relation to the endothelial nitric oxide synthase gene Glu298Asp and intron 4 polymorphisms in a population-based family study. J Human Hypertens. 2005;19:413–420
  17. Hingorani AD, Liang CF, Fatibene J, Lyon A, Monteith S, Parsons A, et al. A common variant of the endothelial nitric oxide synthase (Glu298→Asp) is a major risk factor for coronary artery disease in the UK. Circulation. 1999;100:1515–1520
  18. Nassar BA, Bevin LD, Johnstone DE, O'neill BJ, Bata IR, Kirkland SA, et al. Relationship of the Glu298Asp polymorphism of the endothelial nitric oxide synthase gene and early-onset coronary artery disease. Am Heart J. 2001;142:586–589
  19. McNamara DM, Holubkov R, Postava L, Ramani R, Janosko K, Mathier M, et al. The Asp298 variant of endothelial nitric oxide synthase: effect on survival for patients with congestive heart failure. Circulation. 2003;107:1598–1602
  20. Taylor JS, Ellis GR. Racial differences in responses to drug treatment: implications for pharmacotherapy of heart failure. Am J Cardiovasc Drugs. 2002;2:389–399
  21. Tanus-Santos JE, Desai M, Flockhart DA. Effects of ethnicity on the distribution of clinically relevant endothelial nitric oxide variants. Pharmacogenetics. 2001;11:719–725
  22. McNamara DM, Holubkov R, Postava L, Janosko K, MacGowan GA, Mathier M, et al. Pharmacogenetic interactions between ACE inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. J Am Coll Cardiol. 2004;44:2019–2026
  23. Cohn JN, Tam SW, Anand IS, Taylor AL, Sabolinski ML, Worcel M, et al. Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT. J Card Fail. 2007;13:331–339
  24. Marroni AS, Metzger IF, Souza-Costa DC, Nagassaki S, Sandrim VC, Correa RX, et al. Consistent interethnic difference in the distribution of clinically relevant endothelial nitric oxide synthase genetic polymorphisms. Nitric Oxide. 2005;12:177–182
  25. Zhu H, Wang X, Dong Y, Treiber FA, Sniederet H. Influence of the eNOS gene on development of blood pressure and left ventricular mass: longitudinal findings in multiethnic youth. Pharmacogenet Genom. 2005;15:669–675
  26. Tesauro M, Thompson WC, Rogliani P, et al. Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298. PNAS. 2000;97:2832–2835
  27. Nakayama M, Yasue H, Yoshimura M, et al. T-786-->C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation. 1999;99:2864–2870
  28. Wang J, Dudley D, Wang XL. Haplotype-specific effects on endothelial NO synthase promoter efficiency: modifiable by cigarette smoking. Arterioscler Thromb Vasc Biol. 2002;22:e1–e4
  29. Zhu H, Wang X, Dong Y, Treiber FA, Snieder H. Influence of the eNOS gene on development of blood pressure and left ventricular mass: longitudinal findings in multiethnic youth. Pharmacogenet Genom. 2005;15:669–675
  30. Nejatizadeh A, Kumar R, Stobdan T, Goyal AK, Sikdar S, Gupta M, et al. Endothelial nitric oxide synthase gene haplotypes and circulating nitric oxide levels significantly associate with risk of essential hypertension. Free Radic Biol Med. 2008;44:1912–1918
  31. Scherrer-Crosbie M, Ullrich R, Bloch KD, Nakajima H, Nasseri B, Aretz HT, et al. Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice. Circulation. 2001;104:1286–1291
  32. Yang XP, Liu YH, Shesely EG, Bulagannawar M, Liu F, Carretero OA. Endothelial nitric oxide gene knockout mice cardiac phenotypes and the effect of angiotensin-converting enzyme inhibitor on myocardial ischemia/reperfusion injury. Hypertension. 1999;34:24–30
  33. Stein B, Frank P, Schmitz W, Scholz H, Thoenes M. Endotoxin and cytokines induce direct cardiodepressive effects in mammalian cardiomyocytes via induction of nitric oxide synthase. J Mol Cell Cardiol. 1996;28:1631–1639
  34. Shinke T, Takaoka H, Takeuchi M, Hata K, Kawai H, Okubo H, et al. Nitric oxide spares myocardial oxygen consumption through attenuation of contractile response to β-adrenergic stimulation in patients with idiopathic dilated cardiomyopathy. Circulation. 2000;101:1925–1930
  35. Yamamoto S, Tsutsui H, Tagawa H, Saito K, Takahashi M, Tada H, et al. Role of myocyte nitric oxide in beta-adrenergic hyporesponsiveness in heart failure. Circulation. 1997;95:1111–1114
  36. Hare JM. Stamler JS NO/redox disequilibrium in the failing heart and cardiovascular system. J Clin Invest. 2005;115:509–517
  37. Hare JM. Nitroso-redox balance in the cardiovascular system. N Engl J Med. 2004;351:2112–2114

 Supported in part by a research grant from NitroMed Inc. and grants from the National Heart, Lung and Blood Institute, contracts K24 HL 69912 and RO1 HL75038. Additonal support was received from the National Center for Research Resources, contract 5P20RR011104.

 Conflict of interest: None.

PII: S1071-9164(08)01052-X

doi: 10.1016/j.cardfail.2008.10.028

Journal of Cardiac Failure
Volume 15, Issue 3 , Pages 191-198 , April 2009

Article Tools

* Image Usage & Resolution